Results 161 to 170 of about 172,168 (267)

Rational Design, Synthesis, and Molecular Docking of Novel Terpene Analogues of Imatinib, and Their Inhibition on Downstream BCR-ABL Signaling. [PDF]

open access: yesPharmaceuticals (Basel)
Mihaylova R   +6 more
europepmc   +1 more source

Second- and Third-Generation BCR-ABL Tyrosine Kinase Inhibitors and the Risk of Pulmonary Arterial Hypertension: A Prevalent New-User Design. [PDF]

open access: yesCirculation
Jambon-Barbara C   +8 more
europepmc   +1 more source

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

open access: yesJournal of Clinical Investigation, 2011
A. Corbin   +5 more
semanticscholar   +1 more source

Combined targeting of GPX4 and BCR-ABL tyrosine kinase selectively compromises BCR-ABL+ leukemia stem cells. [PDF]

open access: yesMol Cancer
Zeng C   +14 more
europepmc   +1 more source

A long noncoding RNA critically regulates Bcr-Abl-mediated cellular transformation by acting as a competitive endogenous RNA

open access: yesOncogene, 2014
G. Guo   +11 more
semanticscholar   +1 more source

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib

open access: yesLeukemia, 2014
B. Hanfstein   +28 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy